Calpain modulators and therapeutic uses thereof
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.
1. A compound having the structure of the formula I-a or I-b:
or a pharmaceutically acceptable salt thereof, wherein:
J, L, M 1 and M 2 are each independently selected from the group consisting of C(R 4 ) and N;
each R 4 is independently selected from the group consisting of —H, C 1-4 alkyl, C 3-7 carbocyclyl, halo, hydroxy, and C 1 -C 6 alkoxy;
A 2 is selected from the group consisting of optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, —CH═CH—, —OC(O)NH—, —NHC(O)NH—, —NHC(O)O—, —NHC(O)—, —NHC(S)NH—, —NHC(S)O—, —NHC(S)—, and single bond;
A 4 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, optionally substituted C 2 -C 6 alkenyl, and single bond;
A 5 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, optionally substituted C 2 -C 6 alkenyl, and single bond;
A 6 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, optionally substituted C 2 -C 6 alkenyl, and single bond;
A 7 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, optionally substituted C 2 -C 6 alkenyl, and single bond;
y is an integer from 1 to 4;
z is an integer from 0 to 4;
R 1 is selected from the group consisting of H, —CH 2 F, —CH 2 Cl, —COOH, —C(═O)N(R)OR, —CONR 2 R 3 , —CH(CH 3 )═CH 2 , —CH(CF 3 )NR 2 R 3 , —C(F)═CHCH 2 CH 3 ,
and
each R, R 2 , and R 3 are independently selected from H, optionally substituted C 1-4 alkyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1-6 alkoxy, optionally substituted 2- to 5-membered polyethylene glycol, optionally substituted C 3-7 carbocyclyl, optionally substituted 5-10 membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-10 membered heteroaryl; and
R 6 is selected from —H and optionally substituted C 1-4 alkyl.
2. The compound of claim 1 , wherein:
A 4 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, —CH═CH—, and single bond;
A 5 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, —CH═CH—, and single bond;
A 6 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, —CH═CH—, and single bond;
A 7 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, —CH═CH—, and single bond;
R 1 is selected from the group consisting of H, —CH 2 F, —CH 2 Cl, —COOH, —CONR 2 R 3 , —CH(CH 3 )═CH 2 , —CH(CF 3 )NR 2 R 3 , —C(F)═CHCH 2 CH 3 ,
and
each R, R 2 , and R 3 are independently selected from —H, optionally substituted C 1-4 alkyl, optionally substituted C 3-7 carbocyclyl, optionally substituted 5-10 membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-10 membered heteroaryl.
3. The compound of claim 1 , wherein J, L, M 1 , and M 2 are independently selected from the group consisting of CH and N.
4. A compound having the structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, wherein:
A 2 is selected from the group consisting of optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, and optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—,
—CH═CH—, —OC(O)NH—, —NHC(O)NH—, —NHC(O)O—, —NHC(O)—, —NHC(S)NH—, —NHC(S)O—, —NHC(S)—, and single bond;
A 4 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, optionally substituted C 2 -C 6 alkenyl, and single bond;
As is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, optionally substituted C 2 -C 6 alkenyl, and single bond;
A 6 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, optionally substituted C 2 -C 6 alkenyl, and single bond;
A 7 is selected from the group consisting of optionally substituted C 6-10 aryl, optionally substituted 5-10 membered heteroaryl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 3-10 carbocyclyl, —CR 2 —, —S—, —O—, —NR—, optionally substituted C 2 -C 6 alkenyl, and single bond;
y is an integer from 1 to 4;
z is an integer from 0 to 4;
R 6 is independently selected from —H and, optionally substituted C 1-4 alkyl;
R 1 is selected from the group consisting of H, —CH 2 F, —CH 2 Cl, —COOH, —C(═O)N(R)OR, —CONR 2 R 3 , —CH(CH 3 )═CH 2 , —CH(CF 3 )NR 2 R 3 , —C(F)═CHCH 2 CH 3 ,
and
each R, R 2 , and R 3 are independently selected from —H, optionally substituted
C 1-4 alkyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1-6 alkoxy, optionally substituted 2- to 5-membered polyethylene glycol, optionally substituted C 3-7 carbocyclyl, optionally substituted 5-10 membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-10 membered heteroaryl;
J, L, M, M 1 and M 2 are each independently selected from the group consisting of C(R 4 ) and N;
Y is selected from the group consisting of NR 5 , O, and S, or Y is a nitrogen atom bonded to the A 4 group, wherein the A 4 group is —CH 2 —;
X and Z are each independently selected from the group consisting of C(R 4 ) and N;
X 1 is selected from the group consisting of C(R 4 ) and N, or X 1 is a carbon atom bonded to the A 4 group;
each R 4 is independently selected from the group consisting of —H, C 1-4 alkyl, C 3-7 carbocyclyl, halo, hydroxy, and C 1 -C 6 alkoxy; and
R 5 is selected from the group consisting of —H, C 1-4 alkyl, and C 3-7 carbocyclyl.
5. The compound of claim 1 , wherein A 2 is —CH 2 —.
6. The compound of claim 1 , wherein A 2 is —O—.
7. The compound of claim 4 , wherein J, L, M 1 , and M 2 are independently selected from the group consisting of CH and N.
8. The compound of claim 1 , wherein A 4 is —O—.
9. The compound of claim 1 , wherein A 4 is —CH 2 —.
10. The compound of claim 1 , wherein A 5 is —O— or single bond.
11. The compound of claim 1 , wherein z is 0 or 2.
12. The compound of claim 1 , wherein A 6 is selected from the group consisting of single bond, —CH 2 — and —CH═CH—.
13. The compound of claim 1 , wherein A 7 is selected from the group consisting of —CH═CH—, single bond and phenyl.
14. The compound of claim 1 , wherein z is 2 and A 7 is
15. The compound of claim 1 , wherein R 1 is —CONR 2 R 3 .
16. The compound of claim 15 , wherein R 2 is —H and R 3 is optionally substituted C 1-4 alkyl.
17. The compound of claim 16 , wherein R 3 is C 1-4 alkyl or benzyl.
18. A compound having the structure selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.
20. A method of treating fibrotic disease or a secondary disease state or condition thereof, comprising administering to a subject in need thereof, a compound according to claim 1 .
21. The method of claim 20 , wherein the disease is selected from the group consisting of liver fibrosis, renal fibrosis, lung fibrosis, hypersensitivity pneumonitis, interstitial fibrosis, systemic scleroderma, macular degeneration, pancreatic fibrosis, fibrosis of the spleen, cardiac fibrosis, mediastinal fibrosis, myelofibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, fibrotic complications of surgery, chronic allograft vasculopathy and/or chronic rejection in transplanted organs, ischemic-reperfusion injury associated fibrosis, injection fibrosis, cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome, and rheumatoid arthritis.
22. A method for inhibiting calpain, the method comprising contacting a compound of claim 1 with a CAPN1, CAPN2, and/or CAPN9 enzyme residing inside a subject.